IL12B

Across TCGA pan-cancer cohorts, IL12B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IL12B data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL12B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL12B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and SCLC are the cancer types where IL12B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.058	0.712	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.830	.023	24	view →
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
ACC	OS	Median	All	0.140	0.623	.002	12	view →
SKCM	DFS	Median	All	0.136	0.757	.006	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IL12B–HNSC (OS)

Open the HNSC breakdown →